Today: Edwards Lifesciences Corp. (EW) Rating Reiterate by Evercore ISI

Today: Edwards Lifesciences Corp. (EW) Rating Reiterate by Evercore ISI

Edwards Lifesciences Corp. (NYSE:EW)‘s stock had its “hold” rating reaffirmed by stock analysts at Evercore ISI in a report released on Monday.

Several other brokerages have also recently issued reports on EW. Leerink Swann reissued a “buy” rating on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Morgan Stanley reissued a “buy” rating and issued a $140.00 price objective on shares of Edwards Lifesciences Corp. in a research note on Friday, August 19th. Credit Suisse Group AG set a $116.00 price objective on Edwards Lifesciences Corp. and gave the stock a “buy” rating in a research note on Thursday, August 18th. Canaccord Genuity reissued a “buy” rating and issued a $140.00 price objective on shares of Edwards Lifesciences Corp. in a research note on Thursday, August 18th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Edwards Lifesciences Corp. in a research note on Sunday, September 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-two have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $117.68.

Shares of Edwards Lifesciences Corp. (NYSE:EW) traded down 1.75% on Monday, reaching $84.30. The company’s stock had a trading volume of 3,076,297 shares. Edwards Lifesciences Corp. has a one year low of $72.20 and a one year high of $121.75. The firm has a market capitalization of $18.02 billion, a PE ratio of 33.32 and a beta of 0.71. The firm has a 50-day moving average price of $100.51 and a 200 day moving average price of $106.69.

Edwards Lifesciences Corp. (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.68. Edwards Lifesciences Corp. had a return on equity of 24.32% and a net margin of 19.24%. The business had revenue of $739.40 million for the quarter, compared to the consensus estimate of $749.14 million. During the same period in the prior year, the business posted $0.54 earnings per share. The company’s quarterly revenue was up 20.1% compared to the same quarter last year. On average, analysts anticipate that Edwards Lifesciences Corp. will post $2.88 earnings per share for the current fiscal year.

In other news, VP Huimin Wang sold 13,650 shares of Edwards Lifesciences Corp. stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $120.04, for a total transaction of $1,638,546.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Larry L. Wood sold 13,257 shares of Edwards Lifesciences Corp. stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $119.27, for a total transaction of $1,581,162.39. The disclosure for this sale can be found here. 2.37% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Edwards Lifesciences Corp. by 0.7% in the second quarter. Vanguard Group Inc. now owns 18,796,184 shares of the medical research company’s stock valued at $1,874,543,000 after buying an additional 134,432 shares during the last quarter. FMR LLC raised its stake in Edwards Lifesciences Corp. by 1.2% in the second quarter. FMR LLC now owns 12,366,588 shares of the medical research company’s stock valued at $1,233,319,000 after buying an additional 141,713 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Edwards Lifesciences Corp. by 1.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,542,619 shares of the medical research company’s stock valued at $668,218,000 after buying an additional 81,691 shares during the last quarter. BlackRock Fund Advisors raised its stake in Edwards Lifesciences Corp. by 3.4% in the third quarter. BlackRock Fund Advisors now owns 4,337,584 shares of the medical research company’s stock valued at $522,939,000 after buying an additional 143,348 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Edwards Lifesciences Corp. by 1.6% in the third quarter. Ameriprise Financial Inc. now owns 4,320,603 shares of the medical research company’s stock valued at $520,896,000 after buying an additional 66,627 shares during the last quarter. 83.08% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences Corp.

Related posts

Leave a Comment